Abstract
Spreading depression (SD) is an intense and prolonged depolarization in the central nervous systems from insect to man. It is implicated in neurological disorders such as migraine and brain injury. Here, using an in vivo mouse model of focal neocortical seizures, we show that SD may be a fundamental defense against seizures. Seizures induced by topical 4-aminopyridine, penicillin or bicuculline, or systemic kainic acid, culminated in SDs at a variable rate. Greater seizure power and area of recruitment predicted SD. Once triggered, SD immediately suppressed the seizure. Optogenetic or KCl-induced SDs had similar antiseizure effect sustained for more than 30 min. Conversely, pharmacologically inhibiting SD occurrence during a focal seizure facilitated seizure generalization. Altogether, our data indicate that seizures trigger SD, which then terminates the seizure and prevents its generalization.
Similar content being viewed by others
introduction
Spreading depression (also known as spreading depolarization, SD) is an intense but self-limited neuronal and glial depolarization wave that slowly propagates (millimeters/minute) in the gray matter by way of chemical contiguity1. Near-total loss of transmembrane ion gradients during SD precludes action potential generation and silences synaptic transmission for more than a minute. These properties prompted Leão to name the phenomenon “spreading depression” more than 75 years ago2
All known triggers for SD are strong and sustained depolarizing events (e.g., ischemia, trauma) elevating extracellular [K+] above a critical threshold of 12 mM. Yet SD is also the physiological basis of migraine aura3, and how and why such an intense depolarization event is initiated in ostensibly normal brains of migraine sufferers has perplexed scientists for decades. In fact, SD has been observed in the central nervous systems of all species studied to date from insect to man. It appears to be a fundamental intrinsic property of neurons and neuronal ensembles that somehow affords a survival advantage. The nature of the survival advantage (i.e., the selection pressure) and the significance of SD for normal brain function, however, have been a mystery.
Migraine aura and epilepsy are comorbid paroxysmal disorders, and hyperexcitability, also implicated in migraine, is one mechanism that can incite SD. For example, mutations in CaV2.1 voltage-gated calcium channels in familial hemiplegic migraine4 and pharmacological disinhibition by GABAA receptor blockers5 facilitate and trigger SD. Both are also known to predispose to seizures. Moreover, seizures and SD share common triggers1, and seizures can culminate in SD both in experimental animals6,7 and in humans8. Indeed, a mixed dynamic of seizure and SD is predicted by an extended Hodgkin–Huxley model incorporating cell volume changes and oxygen availability, suggesting that seizures and SD represent a dynamic continuum of neuronal membranes 9,10.
These observations raise the intriguing hypothesis that highly focal seizure activity triggers SD, and SD, by its electrical silencing effect, terminates the seizure. Here, we tested this hypothesis by undertaking a comprehensive examination of the reciprocal interactions between highly focal cortical seizures and SD. Our data provide the first direct proof-of-concept for an antiseizure role for SD and implicate highly focal seizures as potential triggers for migraine aura.
Results
Focal cortical seizures induced by topical application of epileptogenic agents
In animals with topical vehicle application (0.9% NaCl), ECoG morphology and power density remained normal and stable for the entire duration of recordings (Fig. 1; setup as in Supplementary Fig. 1B, a). All three epileptogenic agents induced seizures within 10 min after topical application. Seizure morphology, duration, and the increase in ECoG power density within each frequency band differed among the three agents, recorded for a maximum of 4 h (Fig. 1, also see Supplementary Fig. 2 for ECoG at expanded time scale). Potassium channel blocker 4AP (100 mM) induced synchronized monomorphic spiking that gradually evolved into a periodic burst pattern. The electrographic pattern consisted of large amplitude (~400% of baseline) rhythmic discharges that started at ~1 Hz and evolved to ~4 Hz before attenuation. The cycle repeated itself over a ~30-min period. During bursting, the largest peak power density increase was within the δ frequency range (0–4 Hz, 7.3-fold) followed by θ (4–8 Hz, 3.2-fold) and α (8–12 Hz, 3.4-fold) bands. Seizures typically lasted well over 2 h with gradually decreasing synchronization and burst duration. In contrast, GABA-A receptor antagonist PG (188434 IU/ml) induced near-continuous high-amplitude periodic spikes that changed polarity in a subset of experiments after 41 ± 13 min. The electrographic pattern started as ~0.5 Hz spike-wave activity with an amplitude ~250% over baseline and evolved in amplitude to ~600% over baseline with continuous ~0.5 Hz activity. This pattern developed over a ~70-min period. The largest peak power density increase with PG was within the α (13.7-fold) and θ (12.4-fold) bands followed by δ (3.6-fold) band; power increase in the θ band lasted for the duration of the recordings (4 h), while α band power increase resolved within 90 min. The second GABA-A receptor antagonist BIC (5 mM) induced seizures that were similar to PG in morphology and peak power density increase (19.9-fold in α, 13.3-fold in θ, 3.4-fold in δ), but spikes typically remained negative and lasted less than an hour (note time scale on Fig. 1). The electrographic pattern started as ~0.2 Hz spike-wave activity with an amplitude of ~120% of baseline and evolved into ~2 Hz spike-wave activity with an amplitude of ~250%. This pattern developed over a ~40-min period. The epileptogenic effect was concentration-dependent when tested for 4AP and BIC.
Focal cortical seizures trigger spreading depression
Neocortical seizures culminated in one or more SDs associated with large slow (DC) potential shifts in the seizure focus (Fig. 2; setup as in Supplementary Fig. 1B, a). These always propagated to the remote ipsilateral recording site, coupled to characteristic CBV transients on IOS imaging (Supplementary Movie 1). The highest proportion of animals that developed SD was during 4AP-induced seizures (69%, n = 32 mice), followed by PG (33%, n = 9 mice) and BIC (9%, n = 11 mice; p = 0.002, χ2; Fig. 3A). Lower concentrations of 4AP (5 or 30 mM) or BIC (0.005, 0.5, and 1 mM) led to smaller and shorter-lasting concentration-dependent ECoG power density elevations but did not trigger SD (n = 9 total). In most cases, SDs recurred singly or in clusters (Fig. 3B); all recurrent SDs appeared de novo rather than as reentrant or circling SDs on IOS imaging. The frequency of SDs was 0.89 ± 0.22/h, 0.26 ± 0.17/h, and 0.74 ± 0.74/h after 4AP, PG, and BIC, respectively. The overall frequency of SDs decreased over time (only 4AP shown; Fig. 3C) associated with a gradual weakening of seizure power (Fig. 1). Full-field IOS imaging showed that although most SDs originated in the vicinity of the seizure focus, some emerged as far away as the frontal cortex, suggesting that they were triggered by generalized seizure activity (Fig. 3D). Vehicle application did not result in SD.
A proportion of SDs failed to fully penetrate the center of the seizure focus, as previously reported with repetitive ictal events11. These non-penetrant SDs were detected mainly as smaller positive DC shifts (Fig. 3E). The non-penetrant SD proportions for the first and the subsequent SDs were 48% and 50%, respectively, after 4AP, and 33% and 67%, respectively, after PG. In contrast, all SDs penetrated the seizure focus during BIC-induced seizures. The non-penetrant SD rate appeared to increase over time suggesting a growing resistance at the focus (Fig. 3F).
Inhibition by tetrodotoxin confirms seizures as the immediate trigger for SD
To test whether SDs that developed during a seizure is indeed triggered by seizure activity itself rather than by a direct SD-inducing effect of 4AP, we topically pretreated the cortex with the voltage-gated Na+ channel blocker tetrodotoxin (TTX, 30 μM) 30 min before 4AP application (Supplementary Fig. 3; setup as in Supplementary Fig. 1B, b). TTX depressed ECoG power, blocked seizure induction after 4AP (compare with Fig. 1B), and completely prevented SD occurrence (n = 5; p = 0.005 4AP + TTX vs. 4AP alone, χ2). Importantly, at the end of the experiments, we confirmed that TTX did not directly block SD by successfully inducing an SD via topical KCl application at the remote site and detecting the characteristic negative DC potential shift at the TTX application site (Supplementary Fig. 3, upper right panel).
Power density increase in the δ frequency range predicts SD occurrence
We next sought to elucidate the determinants of SD occurrence during focal seizures. Comparison of peak power increase in δ (0–4 Hz), θ (4–8 Hz) and α (8–12 Hz) bands among the three epileptogenic agents showed that δ band power increase was greatest after 4AP (Supplementary Fig. 4A), where SD occurrence rate was also the highest (Fig. 3A). Comparison of ECoG power immediately preceding an SD in the δ, θ and α bands between experiments with or without a spontaneous SD further supported an association between power increase in δ range and SD occurrence (Supplementary Fig. 4B). Of note, arterial blood pressure, pH, pCO2, pO2, and glucose remained within physiological ranges and did not predict SD occurrence in any of the experiments (Supplementary Table 1).
Generalization of seizures across the cortex predicts SD occurrence
In a subset of mice, 4AP-induced epileptiform activity appeared at the remote ipsilateral anterior recording site and the contralateral homotopic recording sites (36% and 26% of animals, respectively) suggesting seizure generalization (Supplementary Fig. 5, representative tracings a-c and representative spectrograms d–e). We, therefore, examined the relationship between generalization and spontaneous SD occurrence in the 4AP cohort. All nine mice that showed electrophysiological evidence of seizure generalization at the remote sites developed an SD, whereas none of the eight mice that never developed an SD showed such generalization (p = 0.031, χ2), suggesting that seizure generalization predicts SD occurrence.
To better examine the relationship between seizure generalization and SDs, we determined the spatial reach of seizures across the cortex by making use of the cortical hyperemic response to seizure activity detected with IOS imaging. The periodic bursts induced by 4AP created conspicuous hyperemic transients on IOS images12 that were locally tightly coupled to epileptic bursts (Supplementary Movie 1; Fig. 4A). Using this surrogate, we tested whether the spatial extent of cortical seizures predicted SD occurrence by placing five regions of interest (ROIs 1–5) 1 mm apart on a line of interest (LOI) extending anteriorly (Fig. 4B). This approach allowed us to visualize the spatial reach of hyperemic transients caused by the periodic burst pattern both along with the LOI and within each ROI over time (Fig. 4C). We found that 69% of all animals (n = 32) showed hyperemic transients at the 4AP application site (Fig. 4D, ROI 1); the rest of the cohort (31%) did not show IOS transients despite the presence of electrographic seizures. The fraction of animals showing hyperemic transients in each ROI decreased as a function of distance such that only 28% of animals showed hyperemic transients farthest from the 4AP application site (i.e., ROI 5). Moreover, the latency to the onset of hyperemic transients in each ROI increased as a function of distance, suggesting that the spatial extent of cortical involvement with seizure activity gradually increased over time. When we segregated the experiments based on SD occurrence, we found that focal cortical seizures spread significantly farther from the 4AP application site in experiments where SDs occurred compared with those without an SD (p = 0.013; Mann–Whitney test; Fig. 4E). The power map of CBV fluctuations linked to cortical bursts confirmed this finding (Fig. 4F for representative maps). These data showed that the wider the spatial reach of cortical seizure activity, the higher the likelihood of spontaneous SD occurrence. Importantly, IOS changes during seizure-induced SDs (see Supplementary Fig. 6 for a representative experiment) were similar to hemodynamic changes during SDs induced by other methods (e.g., topical KCl) in migraine models13,14. When an SD did not penetrate the seizure focus, it did not cause major IOS changes.
SD terminates focal cortical seizures and limits their reemergence
With all three epileptogenic agents, a highly conspicuous effect of SD was seizure suppression that lasted far beyond the characteristic ECoG depression after SD. To systematically test this, we induced SD by topical KCl application at a remote site after seizure onset and quantified its effect on local seizure activity (Fig. 5, setup as in Supplementary Fig. 1B, b). Induced SDs that propagated to and penetrated the seizure focus immediately extinguished all epileptiform activity triggered by 4AP, PG, or BIC. In the wake of SD, ECoG recovered within 10 min but never returned to power levels associated with the seizure activity prior to SD (Fig. 5E). In most cases, seizures did not reignite even when occasional spike activity returned, despite the continued presence of the seizure-inducing agent on the cortex.
Moreover, an SD induced shortly before the application of the seizure-inducing agent diminished the emergence of seizure activity with all three drugs (Fig. 6A). Even when induced 30 min prior to the 4AP application, SD was still capable of depressing seizure intensity for at least 60 min, suggesting that the antiseizure effect of SD lasts more than 90 min (Fig. 6B). These data showed that SD is a powerful and lasting inhibitor of seizure activity.
SD limits the generalization of seizures across the cortex
To determine the effect of induced SD on the spatial reach of seizures across the cortex, we once again used the hyperemia coupled to seizure activity on IOS imaging (Fig. 7). As expected from diminished seizure activity at the focus, an SD induced 30 or 5 min before, or approximately 30 min after 4AP, all decreased seizure generalization assessed by the proportion of distant ROIs showing seizure-induced hyperemia, as well as the average distance from the drug application site (ROI 1) to which the hyperemia reached (Fig. 7B–D, red circles; p = 0.006 for 4AP, p = 0.010 for PG, p = 0.016 for BIC data set; one-way ANOVA).
We also confirmed this by ECoG recordings outside the 4AP site (Supplementary Fig. 7). An SD induced after the generalization of seizure activity to this location strongly suppressed the seizure. The ECoG power returned to the pre-seizure baseline within 10 min but did not reach pre-SD seizure levels for at least 30 min (p < 0.001, one-way ANOVA; Supplementary Fig. 7C). These data suggested that SD also limits seizure generalization. Hence, not only larger areas of the neocortex recruited into the seizure increased the chance of SD occurrence (see Fig. 4E above), but SDs, in turn, diminished the area of neocortex recruited into the seizure, displaying a feedback mechanism to limit seizure generalization.
Optogenetically-induced SDs also show the strong antiseizure effect
Because topical KCl application is an invasive method requiring a craniotomy to trigger SD, we next tested whether optogenetic SDs induced non-invasively through the intact skull in ChR2+ mice15 also suppress seizures. We found that a single optogenetic SD induced approximately 30 min after 4AP application indeed extinguished the focal seizure (Supplementary Fig. 8A) and tended to reduce its spatial reach (Supplementary Fig. 8B), non-invasively confirming the antiseizure effect of SD.
Suppression of spontaneous SD occurrence enhances seizure intensity and generalization
Data thus far strongly suggested that KCl-induced or optogenetic SDs exerted a potent antiseizure effect. We also examined the effect of spontaneous SDs on seizure power and found a significant suppression (Fig. 8). Because the timing of spontaneous SDs was variable among the experiments (unlike induced SDs as above), we only examined the first SD in each experiment. Next, we pharmacologically blocked spontaneous SDs with NMDA receptor blocker MK-801 to test whether eliminating the SDs and thus their antiseizure effect, facilitates 4AP seizures and their generalization. MK-801 decreased the proportion of mice that developed an SD (33%), and reduced SD frequency by more than 80% (0.14 ± 0.06/h, n = 12 mice) compared with control experiments (0.89 ± 0.22/h, n = 32 mice), without suppressing the seizure intensity. On the contrary, SD-suppression by MK-801 facilitated seizure generalization to the ipsilateral and the contralateral remote recording sites (92% and 89%, respectively; Fig. 9A), compared with control animals (see above). Indeed, ECoG power increase after 4AP was significantly larger in both the ipsilateral and the contralateral remote recording sites in the MK-801 group (Fig. 9B). Once again using the hyperemic transients coupled to periodic bursts, we further confirmed robust seizure generalization in both the ipsilateral and the contralateral ROIs after MK-801 on IOS images (Fig. 9C). Altogether, these data indicated that spontaneously occurring SDs during highly focal seizures are capable of exerting an antiseizure effect. Suppression of SD occurrence by MK-801 eliminated this endogenous antiseizure mechanism.
Familial hemiplegic migraine knock-in mice
We next sought to reproduce our findings in a migraine-relevant knock-in mouse model expressing the S218L familial hemiplegic migraine type 1 (FHM1) mutation in the Cav2.1 voltage-gated Ca2+ channels. Topical application of 4AP (100 mM) induced typical seizures in both the FHM1 knock-in mice and their wild-type (WT) littermates (Supplementary Fig. 9). Despite lower peak power levels reached during the seizures, 7 out of 8 FHM1 mutants developed SDs, compared with only 1 out of 6 of their WT littermates (p = 0.008, χ2; Supplementary Fig. 9B). In FHM1 mutants, SDs often occurred in clusters (Supplementary Fig. 9C). The average SD frequency in FHM1 mutants (3.0 ± 0.7 SDs/h) was markedly higher than the WT littermate that developed an SD (1.3 SDs/h), as well as the CD1 mice (0.9 ± 0.2 SDs/h). The majority of SDs in FHM1 mutants penetrated the seizure focus and thus were associated with negative DC potentials shifts. However, the DC shift amplitude decreased over time suggesting a gradually developing resistance to SD at the seizure focus similar to CD1 mice (Supplementary Fig. 9D). More importantly, spontaneously developing SDs in FHM1 mutants also suppressed seizure intensity (Supplementary Fig. 9E).
Generalized seizures upon systemic kainate administration
Lastly, we extended our findings to a generalized seizure model using systemic kainate injection (60 mg/kg, intraperitoneal in CD1 mice, n = 7). Electrophysiological recordings from the hippocampal CA1 region revealed a characteristic pattern of recurrent seizures consistent with electrographic status epilepticus in all mice that started gradually and gained strength within 30–60 min of kainate administration. Seizures were characterized by rhythmic 15–30 Hz activity with evolution in amplitude to 300% of baseline followed by the onset of 1–2 Hz rhythmic discharges measuring up to 8 mV. Discharges slowed and decreased in amplitude after 15–60 s giving way to post-ictal voltage attenuation. These recurred every 1–3 min with increasing intervals (Fig. 10A). All mice developed a hippocampal SD during kainate seizures. SDs occurred either during a seizure burst or shortly thereafter, the latter suggesting an SD origin farther from the recording site. In the wake of an SD, seizures were completely suppressed for 10 min, and seizure power did not return to pre-SD levels for at least 30 min (Fig. 10B).
Discussion
Our systematic examination using topical application of three different seizure-inducing agents shows that highly focal cortical seizures are capable of triggering SD. Both the ECoG’s greater power increase in the δ frequency band and greater spatial extent of generalization were positive predictors of SD occurrence, which was also enhanced by a human migraine mutation. In turn, SDs suppress seizures for more than 30 min, far beyond the brief electrophysiological silence associated with SD. Generalized seizures upon systemic kainate administration reproduced nearly identical findings.
A unifying theory
Based on these findings, we propose a unifying theory wherein SD is a fundamental endogenous antiseizure mechanism in the central nervous system. As such, SD is triggered if and when synchronized focal neuronal network activity collectively raises extracellular K+ above the 12 mM threshold in a minimum critical volume of tissue, which is estimated to be ~1 mm316. SD then acts as an ‘emergency brake’ or ‘reboot’ extinguishing the seizure and propagates centimeters away from the focus to exert a broader antiseizure effect. The latter is clinically perceived as a migraine aura (Supplementary Movie 2). Clearly, the organism is better off experiencing a migraine aura than seizures, status epilepticus, or generalized convulsions in terms of survival advantage, because they can lead to loss of consciousness, bodily harm, and prolonged post-ictal encephalopathy, and may even be terminal. Therefore, SD can be beneficial in the context of seizures. As such, our theory may explain the evolutionary purpose and persistence of SD.
Our theory can also explain the clinical overlap between epilepsy and migraine with aura, two comorbid, chronic-episodic, paroxysmal disorders. As eloquently outlined by Rogawski17, epilepsy, and migraine with aura share a number of common features: (a) higher prevalence of epilepsy in migraine with aura sufferers than the general population and vice versa18,19; (b) hyperexcitability in both migraine with aura and epilepsy20,21; (c) strong genetic underpinnings (e.g., CACNA1A, ATP1A2, SCN1A, NOTCH3, and PRRT2) associated with both migraine with aura and epilepsy17,22,23; (d) frequent occurrence of postictal migrainous headaches after seizures24,25; and (e) efficacy of antiepileptic drugs, such as valproate and topiramate, in migraine prophylaxis. All these shared features support the notion that microseizures may serve as triggers for migraine aura, i.e., SD. Of course, it unlikely that all auras are triggered by focal seizures and other trigger mechanisms exist.
Relevance for microseizures
Given their average spatial reach of only a few millimeters, the focal epileptiform activity generated in our model was akin to human microseizures that are typically below the spatial detection limit of conventional EEG and only detected using implanted microelectrodes in epilepsy patients, as well as in normal subjects26,27,28. Such localized, subclinical epileptiform activity can in fact precede clinical seizures by many hours29. Microseizures can spread by recruiting neighboring tissue, and as such, act as a precursor or seed for clinically overt seizure activity30. Moreover, microseizures can lead to potentiation of synapses and kindling over time and may be considered an intermediate stage in epileptogenesis31. Given the high rate of SD occurrence we detected under a general anesthetic regimen known to suppress SD susceptibility32, seizures may trigger SD even more frequently in the unanesthetized brain. Once triggered, SD propagates regionally to prevent seizure spread, and perhaps even kindling, thereby exerting a lasting antiepileptic effect. Most importantly, seizures can perpetuate and lead to excitotoxic cell death, whereas in the absence of metabolic compromise, SD is fundamentally self-limiting (typically < 1 min) and non-injurious even after numerous events33, except when prolonged, under hypoxic/ischemic conditions or involving the brainstem 1,34,35.
Evidence from other model systems
Seizures culminating in SD have been observed under various experimental and clinical conditions. For example, focal cortical seizures after topical application of sodium penicillin salt triggered cortical SD waves in rats36, spontaneous focal seizures in both post-cerebral malaria and tetanus toxin mouse models of epilepsy triggered SDs37, focal cortical seizures after electrical stimulation or topical application of 4AP triggered cortical and/or brain stem SD and death in mutant mouse models6,35, and generalized seizures (e.g., maximal electroshock; systemic pentylenetetrazol, tetanus toxin or flurothyl; audiogenic; absence) triggered cortical or subcortical SD in multiple species37,38,39. Moreover, in the acutely injured human brain, subdural recordings showed that more than half of the patients who developed seizures also developed SDs, and in most cases, seizures appeared to trigger SD8. These data suggest that SD triggered by seizure activity is a ubiquitous phenomenon. Even recurrent SDs were predicted by the extended Hodgkin–Huxley model9,10. More importantly, SDs that developed during focal or generalized seizures were associated with seizure termination, after SD seizures did not return for more than 20 min, and when an SD did not develop seizures typically intensified38,39,40,41. Similarly, SDs that developed during seizures in the acutely injured human brain was followed by suppression of seizure activity for more than 15 min even when ECoG activity has recovered8. Mechanically or KCl-induced SDs also potently extinguished and/or prevented focal and generalized seizures, sometimes for more than 90 min42,43,44,45. Altogether, the data strongly suggest that SD is a fundamental endogenous antiepileptic mechanism that is recruited when the intensity of network activity reaches a threshold. Indeed, SDs triggered by acute brain insults (e.g., concussion, intracranial hemorrhage) may also serve to suppress focal seizure activity that might be triggered by the insult, or its generalization, providing yet another potential survival advantage for the organism.
The duration of the antiseizure effect appeared to be highly variable among studies, ranging from just a few minutes to more than 90 min. This was likely due to the intensity of the seizure-inducing stimulus or the chronic epilepsy model used in each study. For example, when high concentrations of drugs were topically applied on a wide area of cortex, seizures returned shortly after SD43, whereas spike-wave discharges in a genetic model of absence epilepsy were suppressed for at least 4 h by a single SD44. The latter is clearly a translationally more relevant model than the topical application of potent seizure-inducing drugs. Therefore, we believe in the majority of cases where weak focal epileptiform activity evolves into a generalized seizure relatively infrequently, the antiseizure effect of SD is likely to be efficacious for longer periods of time. Nevertheless, recurrent seizures also resulted in recurrent SDs in most studies, including ours, which was reminiscent of symptomatic occipital lobe epilepsy presenting with status migrainosus and diffusion-weighted MRI abnormalities consistent with SD46. Regardless of the context, however, on the whole, the occurrence of recurrent SDs significantly reduced the seizure burden in experimental models and is likely to do so in the clinical setting as well. It should be noted that chronic epileptic brains become resistant to SD11,47 and acute but lasting seizures also render the tissue relatively resistant to SD43. This was evident in the failure of many SDs to propagate into the seizure core particularly during the later stages of our experiments as well. Indeed, persistent seizure activity in the process of kindling makes seizures less likely to culminate in SD48.
Potential mechanisms
The mechanisms triggering SD during intense neural activity are almost certainly related to elevated extracellular [K+]. It is also possible that SD occurrence in our model simply reflects the deterioration of tissue health, but this is unlikely as SDs occurred in some cases within mere minutes after seizure onset, at a time when the tissue was robust, healthy, and capable of sustaining more seizures thereafter. The mechanism(s) by which SD exerts its antiseizure effect is more difficult to discern. Profound shifts in extracellular concentrations of most if not all ions, elevated levels of numerous neurotransmitters and neuromodulators, metabolic and hemodynamic alterations, and morphological and gene expression changes, can all contribute to the antiseizure effect to some extent. It has been proposed that the concept of the ictus in epilepsy could be broadened to include a trajectory of seizures terminated by SD, seen in spontaneous epilepsy7 and predicted by biophysics9,10. Given the overlapping cellular and electrophysiological mechanisms of seizures and SD, it is not easy to find an intervention that directly and selectively blocks SD occurrence without affecting the seizures to dissect the causality between these two phenomena and their mechanisms. Any intervention that inhibits one is also likely to directly affect the other. Regardless, data overwhelmingly show that the net effect of SD on seizure activity is a lasting suppression.
Is SD physiological?
Research into SD over the past two decades, heavily in the context of acute brain injury, has portrayed SD as a pathological depolarization state associated with membrane failure. Both as a consequence of and contributor to brain injury, SD signified harm. However, older studies paint a different picture, where SD could be readily induced by single epileptiform spikes36,48, and even by sensory activation if the cortex was hyperexcitable38,49. The latter is intriguing given that migraine attacks can be triggered by sensory stimuli as well50. Intense synaptic activation via long-range inputs could also trigger SD51,52, and spontaneous SDs have been unequivocally demonstrated in genetically susceptible mice35. In fact, SD may be easier to develop than a seizure53, and recent models suggest seizures and SD are part of a dynamic continuum of neuronal membrane state9,10. There are many physiological (i.e., part of normal function, or beneficial) processes that can be pathological when they are overactive or occur at the wrong place and time, and SD might be one of those. When SD occurs in the wrong context (e.g., brain injury), it can have pathological consequences. But even in the injured brain, the interplay of seizures and SD is complex8,54,55,56, and seizures can be terminated by SDs56,57. In conclusion, SD may be an integral part of the brain function and serve fundamental roles (e.g., antiseizure effect). Further research into the potential beneficial effects of SD may reveal other mechanisms that facilitated evolutionary selection and conservation of SD.
Methods
All experiments were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committees and followed the NIH Guide for Use and Care of Laboratory Animals (NIH Publication No. 85-23, 1996).
Animal preparation
We used wild-type mice (n = 165, CD1, male, 3.2 ± 0.1 months, Charles River Laboratories, Wilmington, MA, USA), familial hemiplegic migraine type 1 (FHM1) knockin mice heterozygous for the S218L mutation in the mouse Cacna1a gene encoding for the α1 A pore-forming subunit of CaV2.1 voltage-gated calcium channels (n = 7 males, 1 female; 8.9 ± 2.7 months) and their wild type littermates (n = 4 males, 2 females; 8.3 ± 1.6 months), and transgenic mice expressing channelrhodopsin-2 (ChR2+, n = 10 males and 8 females, 7.5 ± 0.6 months, B6.Cg-Tg(Thy1-COP4/EYFP)18Gfng/J, Jackson Laboratories, Bar Harbor, ME, USA)58,59. Mice were kept under diurnal lighting conditions, room temperature of approximately 25 °C and relative air humidity of 45–65%. Animals were kept in one cage in groups of two to four. The majority of mice were fasted overnight (17.4 ± 0.3 h; n = 173), while a small cohort was studied without fasting (n = 17); results did not differ and were pooled. Before anesthesia induction blood glucose was measured via the tail vein (Accu-Chek Guide, Hague Road, Indianapolis, USA). Mice were then anesthetized with isoflurane (3% induction, 1.25% maintenance) and allowed to breathe spontaneously on a mixture of 70% N2O/30% O2. The femoral artery was cannulated for continuous blood pressure (PowerLab; ADInstruments, Colorado Springs, MO, USA), pCO2, pO2, and pH measurements. Rectal temperature was kept at 36.5–37.0 °C using a thermostatically controlled heating pad (CWE Inc., Ardmore, PA, USA). Mice were then placed on a stereotaxic frame. The skull was exposed, and mineral oil applied to prevent bone drying. Burr holes were drilled under saline cooling and the dura was kept intact.
Cortical electrophysiological recordings and data processing
Slow (DC) potential and electrocorticogram (ECoG) were continuously recorded using epidural glass micropipettes filled with 0.9% saline and a differential extracellular amplifier (bandpass 0.3–300 Hz; EX4-400, Dagan Corporation, Minneapolis, MN) and digitized at 1 kHz for offline analyses (PowerLab; ADInstruments, Colorado Springs, MO, USA). An Ag/AgCl reference electrode was placed subcutaneously in the neck. To eliminate non-physiological signals a 20 Hz digital low-pass filter was applied (Labchart 5 Pro, ADInstruments, Colorado Springs, MO, USA). The ECoG power spectrum density was computed using fast Fourier transform (FFT, cosine-bell window, size 1024, window overlap 93.75%) on 5-min bins of continuous noise-free segments (Labchart 8 Pro, ADInstruments, Colorado Springs, MO, USA). These were then averaged for δ (0–4 Hz), θ (4–8 Hz), α (8–12 Hz) bands, and plotted over time. In addition, time-varying spectrograms were computed using Thomson’s multitaper method (window length 10 s, window step 1 s, bandwidth 20 Hz, number of tapers 9; Chronux toolbox, http://chronux.org; version 2.12 v03, 2018).
Hippocampal recordings
DC potential and ECoG were continuously recorded using a glass micropipette in the hippocampal CA1 region (2 mm posterior and 1.5 mm lateral from bregma at a depth of 1.4 mm). After kainic acid administration isoflurane was gradually lowered from 1.5 to ~0.58 ± 0.08% over 45 min until small-amplitude clonic leg movements appeared as a sign of generalized seizure in the absence of purposeful movements in response to pain.
Intrinsic optical signal (IOS) imaging
We simultaneously performed transcranial IOS imaging of cerebral blood volume (CBV) changes to complement electrophysiological recordings in all experiments to visualize the origins and propagation of SDs and the spatial extent of seizure activity as previously reported12,14,60. IOS imaging started prior to skull drilling to detect inadvertently triggered SDs during the preparation as an exclusion criterion. We achieved skull translucence using topical mineral oil application and diffusely illuminated the skull surface using a white or 530 nm green LED (M530L3, FB530-10, Thorlabs, Newton, NJ, USA) and an aspheric condenser lens (ACL2520U-DG15-A, Thorlabs, Newton, NJ, USA). We acquired full-field images using a USB camera (1 Hz, 640 × 480 pixels; YawCam 0.6.2, 2018). The camera and light source was positioned to minimize surface glare. The green channel of all images was processed with an in-house MATLAB (R2018b) code using the modified Beer-Lambert law as previously described61 to enhance the signal changes reflecting total hemoglobin, and thus CBV. Images were downsampled to 320 × 240 pixels and the reflected light intensity of each pixel in each frame over the whole recording time was calculated. Two lines of interest (LOIs) were placed, one between the drug application site (hereafter referred to as the focus) and the anterior recording site, and one symmetrically on the contralateral hemisphere. In addition, regions of interest (ROIs) were placed along with the LOI at 1-mm intervals, and full-field band power maps were generated, to quantify regional seizure spread.
Drugs
We applied 4-aminopyridine (4AP; 5, 30, or 100 mM; Sigma-Aldrich), penicillin G (PG; 188434 IU/ml, sodium salt; Sigma-Aldrich, St. Louis, MO, USA), 1(S),9(R)-(−)-bicuculline methiodide (BIC; 5 mM; 1 mM, 0.5 mM, 0.05 mM, and 5 µM; Sigma-Aldrich) or vehicle (0.9% saline) topically and repeated it once 10 min later. Cortex was not washed afterwards. In a subset of experiments, tetrodotoxin (TTX; 30 μm in sodium citrate buffer, pH 4.8; Enzo Life Sciences, Farmingdale, NY, USA) was topically applied 30 min prior to 4AP. MK-801 (1 mg/kg, n = 7; 3 mg/kg, n = 5; Sigma-Aldrich) and KA (60 mg/kg; Sigma-Aldrich) were administered intraperitoneally. Topical concentrations and systemic doses were selected based on the literature 6,62,63,64.
Experimental design and setup
Electrophysiology and optical imaging were carried out simultaneously in the same anesthetized animal throughout the experiment (Supplementary Fig. 1A). Various electrode, fiberoptic, and burr hole configurations were used depending on the experimental design. Basic configurations used in the majority of experiments are shown in Supplementary Fig. 1B. Variations to this configuration, when present, are indicated on subsequent figures where the relevant data are presented. The maximum duration of recordings was 240 min. We stopped the recordings if seizure activity diminished (<3 spikes/20 s) for at least 10 min suggesting waning of drug effect (n = 10). Three experiments (76, 90, and 117 min) were additional controls done at later stages of the project to ensure the stability of the model system, and to record high-quality movies. Only one wild type and two FHM1 mice died during the recordings.
Rigor and statistics
Real-time electrophysiological recordings and IOS images precluded blinding. In the absence of a priori experience with the experimental approach, sample sizes were chosen empirically. Data were analyzed using Prism 8 (GraphPad Software) and expressed as mean and standard error. Statistical tests used for each dataset and the sample sizes are indicated where they are presented in text, on the figures, or in figure legends.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request. Source data are provided with this paper.
Code availability
The MATLAB code for calculating CBV changes can be accessed through the following link: https://github.com/it078/CBV_Pixel_Analysis_Seizure_Spread.git.
References
Dreier, J. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat. Rev. 17, 439–447 (2011).
Leao, A. Spreading depression of activity in the cerebral cortex. J. Neurophysiol. 7, 359–390 (1944).
Lauritzen, M. et al. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J. Cereb. Blood Flow. Metab. 31, 17–35 (2011).
Eikermann-Haerter, K. et al. Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J. Clin. Invest. 119, 99–109 (2009).
Köhling, R. et al. Differential sensitivity to induction of spreading depression by partial disinhibition in chronically epileptic human and rat as compared to native rat neocortical tissue. Brain Res. 975, 129–134 (2003).
Aiba, I. & Noebels, J. Spreading depolarization in the brainstem mediates sudden cardiorespiratory arrest in mouse SUDEP models. Sci. Transl. Med. 7, 282ra46 (2017).
Bahari, F. et al. Seizure-associated spreading depression is a major feature of ictal events in two animal models of chronic epilepsy. bioRxiv 455519 (2020).
Fabricius, M. et al. Association of seizures with cortical spreading depression and peri-infarct depolarisations in the acutely injured human brain. Clin. Neurophysiol. 119, 1973–1984 (2008).
Ullah, G. et al. The role of cell volume in the dynamics of seizure, spreading depression, and anoxic depolarization. PLoS Comput. Biol. 11, e1004414 (2015).
Wei, Y., Ullah, G. & Schiff, S. J. Unification of neuronal spikes, seizures, and spreading depression. J. Neurosci. 34, 11733–11743 (2014).
Maslarova, A. et al. Chronically epileptic human and rat neocortex display a similar resistance against spreading depolarization in vitro. Stroke 42, 2917–2922 (2011).
Zhao, M. et al. Spatiotemporal dynamics of perfusion and oximetry duringictal discharges in the rat neocortex. J. Neurosci. 29, (2009).
Yuzawa, I. et al. Cortical spreading depression impairs oxygen delivery and metabolism in mice. J. Cereb. Blood Flow. Metab. 32, 376–386 (2012).
Chung, D. Y. et al. Real-time non-invasive in vivo visible light detection of cortical spreading depolarizations in mice. J. Neurosci. Methods 309, 143–146 (2018).
Chung, D. Y. et al. Determinants of optogenetic cortical spreading depolarizations. Cereb. Cortex 29, 1150–1161 (2019).
Matsuura, T. & Bures, J. The minimum volume of depolarized neural tissue required for triggering cortical spreading depression in rat. Exp. Brain Res. 12, 238–249 (1971).
Rogawski, M. A. Migraine and epilepsy-shared mechanisms within the family of episodic disorders. In Jasper’s Basic Mechanisms of the Epilepsies. 4th edn, Vol. 2012 (eds Rogawski, M. A. et al.) (Oxford University Press, USA, 2012).
Haut, S. R., Bigal, M. E. & Lipton, R. B. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol. 5, 148–157 (2006).
Ottman, R. & Lipton, R. B. Comorbidity of migraine and epilepsy. Neurology 44, 2105–2110 (1994).
Charles, A. C. & Baca, S. M. Cortical spreading depression and migraine. Nat. Rev. Neurol. 9, 637–644 (2013).
Goadsby, P. J. et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol. Rev. 97, 553–622 (2017).
Riant, F. et al. PRRT2 mutations cause hemiplegic migraine. Neurology 79, 2122–2124 (2012).
Chioza, B. et al. Association between the alpha(1a) calcium channel gene CACNA1A and idiopathic generalized epilepsy. Neurology 56, 1245–1246 (2001).
Ito, M. et al. Characteristics of postictal headache in patients with partial epilepsy. Cephalalgia 24, 23–28 (2004).
Panayiotopoulos, C. P. Elementary visual hallucinations, blindness, and headache in idiopathic occipital epilepsy: differentiation from migraine. J. Neurol. Neurosurg. Psychiatry 66, 536–540 (1999).
Stead, M. et al. Microseizures and the spatiotemporal scales of human partial epilepsy. Brain 133, 2789–2797 (2010).
Schevon, C. A. et al. Microphysiology of epileptiform activity in human neocortex. J. Clin. Neurophysiol. 25, 321–330 (2008).
Worrell, G. A. et al. High-frequency oscillations in human temporal lobe: simultaneous microwire and clinical macroelectrode recordings. Brain 131, 928–937 (2008).
Litt, B. et al. Epileptic seizures may begin hours in advance of clinical onset: a report of five patients. Neuron 30, 51–64 (2001).
Merricks, E. M. et al. Single unit action potentials in humans and the effect of seizure activity. Brain 138(Pt 10), 2891–2906 (2015).
Bragin, A., Wilson, C. L. & Engel, T. J. Chronic epileptogenesis requires development of a network of pathologically interconnected neuron clusters: a hypothesis. Epilepsia 41, S144–S152 (2000).
Kudo, C. et al. The impact of anesthetics and hyperoxia on cortical spreading depression. Exp. Neurol. 212, 201–206 (2008).
Nedergaard, M. & Hansen, A. J. Spreading depression is not associated with neuronal injury in the normal brain. Brain Res. 449, 395–398 (1988).
Aiba, I. & Noebels, J. L. Spreading depolarization in the brainstem mediates sudden cardiorespiratory arrest in mouse SUDEP models. Sci. Transl. Med. 7, 282ra46 (2015).
Loonen, I. C. M. et al. Brainstem spreading depolarization and cortical dynamics during fatal seizures in Cacna1a S218L mice. Brain 142, 412–425 (2019).
Koroleva, V. I. & Bures, J. Cortical penicillin focus as a generator of repetitive spike-triggered waves of spreading depression in rats. Exp. Brain Res. 51, 291–297 (1983).
Bahari, F. et al. Spreading depression and seizure unification experimentally observed in epilepsy. bioRxiv 455519 (2018).
Vinogradova, L. V., Vinogradov, V. Y. & Kuznetsova, G. D. Unilateral cortical spreading depression is an early marker of audiogenic kindling in awake rats. Epilepsy Res. 71, 64–75 (2006).
Vinogradova, L. V., Kuznetsova, G. D. & Coenen, A. M. Audiogenic seizures associated with a cortical spreading depression wave suppress spike-wave discharges in rats. Physiol. Behav. 86, 554–558 (2005).
Bragin, A., Penttonen, M. & Buzsaki, G. Termination of epileptic afterdischarge in the hippocampus. J. Neurosci. 17, 2567–2579 (1997).
Zakharov, A. et al. Segregation of seizures and spreading depolarization across cortical layers. Epilepsia 60, 2386–2397 (2019).
Kesner, R. P., O’Kelly, L. I. & Thomas, G. J. Effects of cortical spreading depression and drugs upon audiogenic seizures in rats. J. Comp. Physiol. Psychol. 59, 280–282 (1965).
Ueda, M. & Bures, J. Differential effects of cortical speading depression on epileptic foci induced by various convulsants. Electroencephalogr. Clin. Neurophysiol. 43, 666–674 (1977).
Samotaeva, I. S. et al. Intracortical microinjections may cause spreading depression and suppress absence seizures. Neuroscience 230, 50–55 (2013).
Kelly, M. E., Battye, R. A. & McIntyre, D. C. Cortical spreading depression reversibly disrupts convulsive motor seizure expression in amygdala-kindled rats. Neuroscience 91, 305–313 (1999).
Striano, P. et al. Status epilepticus migrainosus: clinical, electrophysiologic, and imaging characteristics. Neurology 76, 761 (2011). author reply 761.
Guedes, R. C. & Cavalheiro, E. A. Blockade of spreading depression in chronic epileptic rats: reversion by diazepam. Epilepsy Res. 27, 33–40 (1997).
Koroleva, V. I., Vinogradova, L. V. & Bures, J. Reduced incidence of cortical spreading depression in the course of pentylenetetrazol kindling in rats. Brain Res. 608, 107–114 (1993).
Vinogradova, L. V., Kuznetsova, G. D. & Coenen, A. M. Unilateral cortical spreading depression induced by sound in rats. Brain Res. 1286, 201–207 (2009).
Coppola, G., Pierelli, F. & Schoenen, J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia 27, 1427–1439 (2007).
Ochs, S., Hunt, K. & Booker, H. Spreading depression using chronically implanted electrodes. Am. J. Physiol. 200, 1211–1214 (1961).
Grafstein, B. Mechanism of spreading cortical depression. J. Neurophysiol. 19, 154–171 (1956).
Vinogradova, L. V. Initiation of spreading depression by synaptic and network hyperactivity: insights into trigger mechanisms of migraine aura. Cephalalgia 38, 1177–1187 (2018).
Dreier, J. P. et al. Spreading convulsions, spreading depolarization and epileptogenesis in human cerebral cortex. Brain 135(Pt 1), 259–275 (2012).
Hartings, J. A. et al. Spreading depolarisations and outcome after traumatic brain injury: a prospective observational study. Lancet Neurol. 10, 1058–1064 (2011).
Schoknecht, K. et al. The role of spreading depolarizations and electrographic seizures in early injury progression of the rat photothrombosis stroke model. J. Cereb. Blood Flow. Metab. 41, 271678X20915801 (2020).
Hartings, J. A., Tortella, F. C. & Rolli, M. L. AC electrocorticographic correlates of peri-infarct depolarizations during transient focal ischemia and reperfusion. J. Cereb. Blood Flow. Metab. 26, 696–707 (2006).
Wang, H. et al. High-speed mapping of synaptic connectivity using photostimulation in Channelrhodopsin-2 transgenic mice. Proc. Natl Acad. Sci. USA 104, 8143–8148 (2007).
Arenkiel, B. R. et al. In vivo light-induced activation of neural circuitry in transgenic mice expressing channelrhodopsin-2. Neuron 54, 205–218 (2007).
Zhao, M. et al. Preictal and ictal neurovascular and metabolic coupling surrounding a seizure focus. J. Neurosci. 31, 13292-13300 (2011).
Ma, Y. et al. Wide-field optical mapping of neural activity and brain haemodynamics: considerations and novel approaches. Philos Trans R Soc Lond B. 371, 20150360 (2016).
Liou, J. Y. et al. Role of inhibitory control in modulating focal seizure spread. Brain 141, 2083–2097 (2018).
Akdogan, I. et al. Penicillin-induced epilepsy model in rats: dose-dependant effect on hippocampal volume and neuron number. Brain Res. Bull. 77, 172–177 (2008).
Pitkanen, A., Schwartzkroin, P. A. & Moshe, S. L. Models of Seizures and Epilepsy. (Elsevier, 2006).
Acknowledgements
This work was funded by NIH (R01NS102969 to C.A., 2R01EB014641 to S.J.S.).
Author information
Authors and Affiliations
Contributions
I.T. conceived the study, designed and performed experiments and data analysis, wrote the manuscript, and drew the figure illustrations. C.A. conceived the study, designed experiments and data analysis, performed circuit reconstruction and wrote the manuscript. D.C. contributed data analysis, experimental design, and revision of the manuscript. A.L. contributed to experimental design. I.L. contributed to revision experiments. T.Q. contributed reagents. A.M., F.S., M.E., and S.J.S. revised the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Peer review information Nature Communications thanks Jed Hartings and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Source data
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tamim, I., Chung, D.Y., de Morais, A.L. et al. Spreading depression as an innate antiseizure mechanism. Nat Commun 12, 2206 (2021). https://doi.org/10.1038/s41467-021-22464-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41467-021-22464-x
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.